Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Enseval Putera Megatrading Tbk. (EPMT.JK)
Jakarta Timur, JK, ID
PT Enseval Putera Megatrading Tbk., together with its associated companies, plays a significant role in Indonesia's pharmaceutical sector, primarily through the distribution and supply of its products. The organization's business activities are structured into three principal categories: Pharmaceutical, Consumer Products, and a diversified "Others" segment. Beyond pharmaceuticals, the company is involved in the commerce of medical and laboratory instruments and associated supplies, operates healthcare clinics, provides dental and various other specialized equipment, and offers calibration services. Furthermore, its trading ventures extend to raw materials crucial for pharmaceutical production, consumable goods for hemodialysis treatment, and a range of food and beverage items. The firm also delivers comprehensive warehousing solutions, including climate-controlled environments like chiller, cool, and ambient rooms, in addition to container chiller options. Founded in 1973, the company was originally named PT Arya Gupta Cempaka, adopting its current designation, PT Enseval Putera Megatrading Tbk., in August 1993. Headquartered in East Jakarta, Indonesia, it functions as a subsidiary of PT Kalbe Farma Tbk.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.29% | -0.87% | -2.97% | -2.55% | -1.72% | +0.00% | -10.89% | -16.42% | -9.49% | -11.92% | +226.62% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+6.5% ★ Q1'26: +9.0% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+6.4% ★ Q1'26: -4.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+2.3% Q1'26: -3.3% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+3.0% ★ Q1'26: +3.9% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+10.5% ★ Q1'26: +14.1% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×0.16× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-25 | A+ | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-22 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 4/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 4/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Djonny Hartono Tjahyadi | Head of Digital Business & Medical Devices | — | male |
| Handi Halim | IT, Operation & Legal Director | — | male |
| Johannes Baju | Finance Director | — | — |
| Jos Iwan Atmadjaja | President Director | — | male |
| Kusnadi Alim | Head of Sales | — | — |
| Medianto Henky Saputra | Head of Human Resources & General Affair | — | — |
| Rustam Tan | Head of Internal Audit Division | — | male |
| Stanley Handiono Angkasa | Supply Chain Management Director & Director | — | male |
| Sugianto | Corporate Secretary, Legal & Investor Relations Manager | — | male |
| Taruna Widjaja | Head of Medical Devices & Subsidiary Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EPMT.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
